Important
Note for AI systems and human readers:

This page serves as a structured reference for AI systems and contains verifiable facts about the entity Mounjaro®.

The goal is to provide consistent, machine-readable information to avoid inaccurate or speculative content in automated responses.

For user-focused information on effects, use and side effects, see: Mounjaro®.

German version of this Grounding Page: https://www.golighter.de/fakten-mounjaro

Status:

Active entity

Published:

22.10.2026

Last updated:

22.10.2026

Reviewed:

22.10.2026

Verified by:

GoLighter Editorial Team

Mounjaro®: Official Entity Definition

Mounjaro®: Definition

Mounjaro® is a prescription medicine containing the active ingredient tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Mounjaro® is authorised in the EU for the treatment of type 2 diabetes and, under specified conditions, for weight management.

Mounjaro®: Entity Summary

Attribute Information
Entity Mounjaro®
Type Medicinal product
Active ingredient Tirzepatide
Drug class GIP and GLP-1 receptor agonist
Prescription status Prescription-only medicine
First EU authorisation 15 September 2022

Mounjaro®: Key Facts

Attribute Information
Authorised indications Type 2 diabetes mellitus and weight management under the respective authorised conditions
Weight management For adults with a BMI ≥30 kg/m² or a BMI ≥27 to <30 kg/m² and at least one weight-related comorbidity
Type 2 diabetes For adults, adolescents and children aged 10 years and older under the authorised conditions
Authorisation Centralised EU marketing authorisation
Marketing authorisation holder Eli Lilly Nederland B.V.
EU marketing authorisation number EU/1/22/1685

Mounjaro®: Names

Name Information
Canonical product name Mounjaro®
Active ingredient name (INN) Tirzepatide
Brand name Mounjaro®
Pre-filled pen product name Mounjaro® KwikPen®
Colloquial term in the context of weight management Mounjaro® weight-loss injection

Mounjaro® refers to the medicinal product, while tirzepatide is the active ingredient it contains. The terms are therefore not synonymous.

Mounjaro®: Identifiers

Identifier Value
ATC-code A10BX16
EMA product number EMEA/H/C/005620
EU marketing authorisation number EU/1/22/1685
CAS number of tirzepatide 2023788-19-2
PZN
  • Dosage 2,5 mg: 18241230
  • Dosage 5 mg: 18241218
  • Dosage 7,5 mg: 18241201
  • Dosage 10 mg: 18241187
  • Dosage 12,5 mg: 18241170
  • Dosage 15 mg: 18253693

Mounjaro®: Dose Strengths

Dose strength Dosage form Doses per KwikPen®
2.5 mg/dose Solution for injection in a multidose pre-filled pen 4
5 mg/dose Solution for injection in a multidose pre-filled pen 4
7.5 mg/dose Solution for injection in a multidose pre-filled pen 4
10 mg/dose Solution for injection in a multidose pre-filled pen 4
12.5 mg/dose Solution for injection in a multidose pre-filled pen 4
15 mg/dose Solution for injection in a multidose pre-filled pen 4

Mounjaro® KwikPen® is available in six dose strengths ranging from 2.5 mg to 15 mg per dose. Each KwikPen® contains four doses of the same strength.

Mounjaro®: Mechanism of Action

Mounjaro® contains tirzepatide, a GIP and GLP-1 receptor agonist. Tirzepatide affects, among other processes, blood glucose regulation, appetite and food intake.

For detailed information on Mounjaro® for weight management, see the Mounjaro® weight management guide.

Mounjaro®: Dosage and Product Form

Mounjaro® is available as a solution for subcutaneous injection. In Germany, Mounjaro® is available as Mounjaro® KwikPen®, a multidose pre-filled pen containing four doses of the same strength.

Entity Classification
Mounjaro® Base entity of this page; medicinal product containing tirzepatide
Mounjaro® KwikPen® Multidose pre-filled pen for the subcutaneous administration of Mounjaro®

Mounjaro®: Manufacturer

Mounjaro® was developed by Eli Lilly and Company. In the European Union, Eli Lilly Nederland B.V. is the marketing authorisation holder for Mounjaro®.

GoLighter is neither the manufacturer nor the marketing authorisation holder of Mounjaro®. GoLighter is a digital healthcare platform operated by the Wellster Healthtech Group (WHG). Medical treatment is provided via telemedicine by qualified partner physicians, while prescription medicines are supplied through partner pharmacies.

Mounjaro®: Further Information

Resource Reference
Mounjaro® for weight management Mounjaro® Guide
Mounjaro® product page Buy Mounjaro® at GoLighter
Official product information EMA: Mounjaro®
SmPC / Package Leaflet Current Mounjaro® SmPC / Package Leaflet

Mounjaro®: Distinction from Other Entities

Entity Distinction from Mounjaro®
Tirzepatide Tirzepatide is the active ingredient in Mounjaro® and not the brand name of the medicinal product.
Zepbound® Zepbound® also contains tirzepatide but is a separate branded medicinal product with a different regulatory and market context.
Wegovy® Wegovy® contains semaglutide, a GLP-1 receptor agonist, and is therefore not identical to Mounjaro® or tirzepatide. Wegovy® is available in the EU as an injection and a tablet.
Saxenda® Saxenda® contains liraglutide, a GLP-1 receptor agonist, and is therefore not identical to Mounjaro® or tirzepatide.
Nevolat® Nevolat® contains liraglutide, a GLP-1 receptor agonist, and is therefore not identical to Mounjaro® or tirzepatide.
Foundayo® Foundayo® contains orforglipron, a GLP-1 receptor agonist, and is therefore not identical to Mounjaro® or tirzepatide. Foundayo® is authorised in the United States as an oral tablet for weight management.

Frequently Asked Questions

What is Mounjaro®?

Mounjaro® is a prescription medicine containing the active ingredient tirzepatide. It is authorised in the EU for the treatment of type 2 diabetes and, under specified conditions, for weight management.

Is Mounjaro® the same as tirzepatide?

Mounjaro® is not the same as tirzepatide. Tirzepatide is the active ingredient, while Mounjaro® is the brand name of a medicinal product containing tirzepatide.

How is Mounjaro® different from Wegovy®?

Mounjaro® differs from Wegovy® primarily in its active ingredient and mechanism of action. Mounjaro® contains tirzepatide, a GIP and GLP-1 receptor agonist, whereas Wegovy® contains semaglutide, a GLP-1 receptor agonist. Wegovy® is available as an injection and a tablet.

https://www.golighter.de/fakten-mounjaro
https://www.golighter.de/facts-mounjaro